Literature DB >> 6786470

Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods.

W H Inman.   

Abstract

Spontaneous reporting of suspected adverse drug reactions through the yellow card system provides an effective means of early warning of potentially serious drug effects but occasionally fails because of under-reporting. Since more than 80% of medicines are prescribed by general practitioners we look to them to support new methods of postmarketing surveillance. No single method will be appropriate for all drugs, and yellow cards will always be required to detect rare events. It is proposed that adverse events experienced by the first 10 000 patients who receive certain new medicines should be recorded and transmitted to a monitoring centre and that a realistic target, which should be reached early in the market life of a new medicine, is the detection of any adverse event that occurs in more than in 1000 patients.

Entities:  

Mesh:

Year:  1981        PMID: 6786470      PMCID: PMC1505052          DOI: 10.1136/bmj.282.6270.1131

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  1 in total

1.  Monitoring adverse reactions to drugs.

Authors:  C T Dollery; M D Rawlins
Journal:  Br Med J       Date:  1977-01-08
  1 in total
  12 in total

1.  A survey of adverse drug reactions in family practice.

Authors:  J L Reynolds
Journal:  Can Fam Physician       Date:  1984-01       Impact factor: 3.275

Review 2.  Principles of signal detection in pharmacovigilance.

Authors:  R H Meyboom; A C Egberts; I R Edwards; Y A Hekster; F H de Koning; F W Gribnau
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

3.  Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

4.  The role of record linkage in post-marketing drug surveillance.

Authors:  I K Crombie
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

5.  Adverse Drug Reaction Reporting Program of the Ontario Medical Association: the first 3 years.

Authors:  C W Gowdey; M Brennan
Journal:  Can Med Assoc J       Date:  1985-01-01       Impact factor: 8.262

6.  Long-term assessment of drug safety and efficacy.

Authors:  P Turner
Journal:  J R Soc Med       Date:  1984-02       Impact factor: 5.344

7.  Monitoring of drugs after marketing.

Authors: 
Journal:  J R Coll Gen Pract       Date:  1983-07

8.  European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.

Authors:  D H Lawson; K Bridgman; G H de Bock; D E Grobbee; H W Hense; P Block; K R Paterson; P Stonier
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  The measurement of morbidity in general practice.

Authors:  D M Fleming
Journal:  J Epidemiol Community Health       Date:  1991-09       Impact factor: 3.710

10.  Multiple hospital admissions in a calendar year.

Authors:  J Newton; M Goldacre
Journal:  J Public Health Med       Date:  1993-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.